EUVIMEDEUVIMED entdecken
Systematische Übersicht

Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review

Jacob Surma, Jenna Currier, David Doyle, Mackenzy Maddock, Garrett Borgman, Cassandra DeGroat, Sierra Demarinis, Natalie Aguilar, Spencer Williams, Patrick Fakhoury, Robert Stachler

Clinical Drug Investigation · 2026-09 · 46 (9) · 931-964

DOI: 10.1007/s40261-026-01573-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Drug Investigation, online erschienen am 29.06.2026. Verfasst von Jacob Surma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Covenant Healthcare College of Medicine at Central Michigan University, Saginaw, MI, 48602, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Quality of Life, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that disproportionately affects children, often causing significant physical, psychological, and social burdens. While biologic therapies have transformed AD management in adults, pediatric-specific evidence remains limited. Dupilumab, an interleukin (IL)-4 receptor α antagonist that inhibits IL-4 and IL-13 signaling, is currently the only US Food and Drug Administration (FDA)-approved biologic for pediatric AD. OBJECTIVE: To systematically review the efficacy, safety, quality of life, and adherence of dupilumab in children (0-12 years) with moderate-to-severe AD. METHODS: This review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed, Embase, and Cochrane Library were searched from inception to August 10, 2024, for studies involving biologic use in pediatric AD. Eligible designs included randomized controlled trials (RCTs), open-label extensions, observational studies, case series, and case reports reporting validated efficacy, safety, quality of life, or adherence outcomes. Risk of bias was assessed using the Mixed Methods Appraisal Tool (MMAT). Results were synthesized narratively, stratified by study design and age group; meta-analysis was not performed due to heterogeneity in study designs, outcome measures, and follow-up durations. RESULTS: Of 1576 records screened, 20 studies (n= around 1200; age range: 5 months to 12 years) met inclusion criteria. Across study designs, dupilumab produced rapid and sustained improvements in disease severity, with mean Eczema Area and Severity Index (EASI) reductions of 62-92% and high EASI-75 response rates (53-94%) within 16-52 weeks. Quality of life gains were substantial, including large reductions in Children's Dermatology Life Quality Index scores (up to ~89%) and marked sleep improvement. Adverse events were generally mild; conjunctivitis (0-20%) was the most common, with rare herpesvirus infections and injection-site reactions. Laboratory abnormalities including eosinophilia and alkaline phosphatase (ALP) elevation were typically asymptomatic and transient. Adherence was high (≥90% in most cohorts), with low discontinuation rates. Data were synthesized across two developmental age groups where possible: children aged 6 months to 5 years and children aged 6 to 11 years. Some studies reported numerically higher or faster responses in younger children (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicQuality of LifeAntibodies, Monoclonal, HumanizedHumansChildChild, PreschoolInfantTreatment Outcome

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Covenant Healthcare College of Medicine at Central Michigan University, Saginaw, MI, 48602, USA.
  • Stachler ENT, West Bloomfield, MI, 48322, USA. robstachler@comcast.net.

Zitieren

APA

Surma, J., Currier, J., Doyle, D., Maddock, M., Borgman, G., DeGroat, C., Demarinis, S., Aguilar, N., Williams, S., Fakhoury, P., & Stachler, R. (2026). Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review. Clinical Drug Investigation, 46(9), 931-964. https://doi.org/10.1007/s40261-026-01573-9

Vancouver

Surma J, Currier J, Doyle D, Maddock M, Borgman G, DeGroat C, et al. Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review. Clinical Drug Investigation. 2026;46(9):931-964. doi:10.1007/s40261-026-01573-9

BibTeX
@article{Surma2026,
  author = {Surma, Jacob and Currier, Jenna and Doyle, David and Maddock, Mackenzy and Borgman, Garrett and DeGroat, Cassandra and Demarinis, Sierra and Aguilar, Natalie and Williams, Spencer and Fakhoury, Patrick and Stachler, Robert},
  title = {Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review},
  journal = {Clinical Drug Investigation},
  year = {2026},
  volume = {46},
  number = {9},
  pages = {931--964},
  doi = {10.1007/s40261-026-01573-9}
}
Kostenlos starten →